Company Strategy & Focus - 908 Devices is shifting its focus to higher-growth handheld markets, specifically targeting public health, safety, and defense applications with chemical analysis tools for CBRNE (Chemical, Biological, Radiological, Nuclear, and Explosives) [9] - The company aims for Adjusted EBITDA profitability in Q4 2025, driven by improved productivity and facility consolidation [9] - 908 Devices is positioned for acceleration due to secular tailwinds in opioid crisis response, defense budgets, and border security, supported by an innovation pipeline and an expanding installed base of over 3,500 devices [10] Financial Performance & Guidance - The company's strategic transformation includes an increase in devices from 2,422 at YE 2023 to over 3,500 by Q3 2025 [43, 45] - 908 Devices projects revenue between $54 million and $56 million for 2025, representing a 13% to 17% year-over-year increase [45] - The company anticipates a year-end cash balance of approximately $110 million in 2025 [45, 52] - The company reported $13.9 million in recurring revenue YTD 2025, which is 36% of total revenue, with a 16% year-over-year revenue growth and a 56% adjusted gross margin [54] Growth Catalysts - Equipment modernization, specifically replacing outdated FTIRs and penetrating new enterprise accounts, is identified as a growth catalyst with a potential of over 15,000 unit opportunity [39, 58] - The launch of the next-generation MX908 is expected to generate a replacement cycle, offering improved performance, simplicity, and a lower cost of goods [39] - The U S Department of Defense AVCAD program in partnership with Smiths Detection represents another growth catalyst [41]

Financial Performance - Network Volume reached $2.802 billion in 3Q'25, a 19% increase compared to $2.351 billion in 3Q'24[12] - Total revenue & other income increased by 36% from $257 million in 3Q'24 to $350 million in 3Q'25[12] - Fee revenue less production costs (FRLPC) grew by 39% from $100 million in 3Q'24 to $139 million in 3Q'25[12] - Adjusted EBITDA increased by 91% from $56 million in 3Q'24 to $107 million in 3Q'25[12] - The company achieved a Net Income of $23 million in 3Q'25, a significant improvement of $90 million compared to a loss of $67 million in 3Q'24[12, 14] Operating Metrics - The company's ABS issuance reached $7.4 billion TTM (Trailing Twelve Months) in 3Q'25[34] - Applications evaluated in 3Q'25 totaled $266 billion, representing a 12% quarter-over-quarter increase[35] - The conversion rate of applications to issued loans was approximately 1% in 3Q'25[35] FRLPC Evolution - FRLPC % (Fee revenue less production costs as a % of network volume) reached 5% in 3Q'25[56], with a target of 4%-5% for 2025[17] - AI integration contributed $309 million to fee revenue in 3Q'25[22]

LYL273 Acquisition and Pipeline - Lyell Immunopharma strengthens its CAR T-cell pipeline with LYL273, a novel GCC-targeted product candidate for metastatic colorectal cancer (mCRC)[1] - LYL273 targets GCC, which is expressed on over 95% of mCRC and a majority of pancreatic cancers[12] - The acquisition includes an upfront payment of $40 million and 1.9 million shares, with potential for additional clinical, regulatory, and commercial milestones plus tiered royalties[12] - Lyell's LyFE manufacturing facility has a capacity for >1,200 doses/year at full capacity[75] Clinical Trial Data and Efficacy of LYL273 - In a U S Phase 1 clinical trial, LYL273 showed a 67% overall response rate at Dose Level 2 in patients with refractory mCRC[12, 32] - The disease control rate was 83% at the highest dose of LYL273 evaluated in the U S Phase 1 clinical trial[12] - In a Chinese study, at Dose Level 2, median OS was 25 months (95% CI, 13 4 to 26 1), median PFS was 6 0 months (95% CI, 3 0 to NA)[24] - One patient in the U S trial achieved a pathological complete response at autopsy[32, 42] Market and Future Milestones - The worldwide projected net sales for colorectal cancer are a $6+ billion market[13, 16] - Lyell anticipates the next data update for LYL273 in the first half of 2026[57, 81] - The company's cash runway extends into 2027, through multiple clinical milestones[81, 85]

Financial Performance - Revenue for Q3 2025 was $1602 million, a 1% increase compared to Q3 2024[13] - Adjusted EBITDA for Q3 2025 was $518 million, with a 323% Adjusted EBITDA margin[13] - Adjusted diluted EPS for Q3 2025 was $101, compared to $087 in Q3 2024, a 16% increase[13] - The full-year revenue range is revised to $6200 million - $6250 million, with an Adjusted EBITDA margin guidance revised to approximately 310%[13] - Free Cash Flow before one-time costs YTD September 2025 was $813 million, compared to $693 million in 2024[32] Revenue Analysis by Segment - Total Women's Health revenue was $429 million in Q3 2025, a decrease of 3% compared to Q3 2024[17] However, year-to-date Women's Health revenue increased by 3% to $1354 million[15,17] - Nexplanon revenue was $223 million in Q3 2025, a decrease of 8% compared to Q3 2024[17] - Total Biosimilars revenue was $196 million in Q3 2025, a 19% increase compared to Q3 2024[20] Year-to-date Biosimilars revenue increased by 2% to $510 million[20] - Hadlima revenue increased by 57% to $63 million in Q3 2025[20] - Total Established Brands revenue was $956 million in Q3 2025, a 1% increase compared to Q3 2024[24] Year-to-date Established Brands revenue decreased by 5% to $2778 million[24] Geographic Performance - United States revenue increased by 2% to $406 million in Q3 2025[56] - Europe and Canada revenue decreased by 4% to $417 million in Q3 2025[56] - Latin America, Middle East, Russia and Africa revenue increased by 18% to $286 million in Q3 2025[56] Guidance - Full-year revenue guidance is revised to $6200 million - $6250 million, representing a nominal revenue growth of (32%) - (24%)[39] - Adjusted EBITDA margin guidance is revised to approximately 310%[39]

Financial Performance - Total revenue reached $28.4 million, compared to $27.2 million in Q3'24[2] - Non-GAAP diluted income per share was 11 cents, down from 14 cents in Q3'24[2] - GAAP diluted income per share was a loss of 10 cents, compared to a loss of 6 cents in Q3'24[2] - Licensing and related revenue increased to $16 million, a 3% year-over-year increase from $15.6 million in Q3'24[4] - Royalties revenue increased to $12.4 million, a 6% year-over-year increase from $11.6 million in Q3'24[4] - Non-GAAP operating income was $3.1 million, compared to $2.1 million in Q3'24[4] - Non-GAAP net income was $3.4 million, compared to $2.7 million in Q3'24[4] Other Key Metrics - The company returned $1 million to shareholders via stock repurchase of 40,295 shares in Q3[9] - $152 million in cash and cash equivalent balances, marketable securities and bank deposits at the end of Q3, debt free[9] - Total units shipped reached 579 million[8]

Q3 2025 Key Performance Indicators - eToro's funded accounts reached 373 million, a 16% year-over-year increase[13] - Assets Under Administration (AUA) totaled $208 billion, marking a 76% year-over-year growth[13] - Net Contribution amounted to $215 million, reflecting a 28% year-over-year increase[13] - Adjusted EBITDA reached $78 million, a 43% year-over-year increase[13] Financial Performance - Net income increased to $57 million, a 48% year-over-year increase[119] - Total money transfers grew to $28 billion, a 58% year-over-year increase[115] - Interest-earning assets rose to $79 billion, a 53% year-over-year increase[111] User Engagement - The number of trades in capital markets/ECC increased to 135 million, a 15% year-over-year increase[106] - The number of cryptoasset trades increased to 16 million, a 73% year-over-year increase[106] - Invested amount per cryptoasset trade increased to $300, a 58% year-over-year increase[106] Strategic Initiatives - eToro announced a $150 million share repurchase program[156] - eToro Money accounts reached 175 million, with debit card issuance increasing 25 times compared to Q2[75]

Financial Performance - Revenue for Q3 FY25 reached $317 million, representing a 26% year-over-year growth[5] - The company's adjusted free cash flow was $92 million, which is 29% of the revenue[5] - Gross margin stands at 90%[5] - Remaining performance obligations (RPO) reached $747 million in Q3 FY25[36] Customer Growth and Retention - Customers with ARR (Annual Recurring Revenue) exceeding $50,000 experienced a 37% year-over-year increase, totaling 3,993[5] - Net dollar retention rate for customers with ARR over $50,000 is 117%[5] - Total customer base has grown at a CAGR of 22% from FY19 to FY24[17] Customer Segmentation - Customers with $50k+ ARR contribute 40% of the total ARR[29] - Customers with $100k+ ARR contribute 27% of the total ARR[29] - Customers with $500k+ ARR contribute 6% of the total ARR[29] Geographical Revenue Distribution - North America accounts for 54% of the company's revenue[23] - Europe contributes 27% to the company's revenue[23] - MEA (Middle East & Africa) accounts for 5% of the company's revenue[23] - APAC (Asia-Pacific) contributes 8% to the company's revenue[23] - Latam (Latin America) accounts for 6% of the company's revenue[23]

3Q 2025 Earnings Call November 10, 2025 Agenda 01 Introduction Ameet Mallik Chief Executive Officer 03 Chief Financial Officer Financial Update Pepe Carmona 04 Q&A 2 Forward-Looking Statements 02 Clinical Highlights Mohamed Zaki Chief Medical Officer This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construe ...

Factor XI Program Overview - Regeneron is developing two Factor XI antibodies, REGN7508Cat and REGN9933A2, targeting various indications with different bleeding risk profiles[51] - The company aims to address unmet needs in anticoagulation by potentially reducing bleeding risk while maintaining efficacy[64] - Genetics support targeting Factor XI, as lower FXI levels are associated with reduced VTE and cardioembolic stroke risk[16, 20] Clinical Data and Development - ROXI-VTE-I and ROXI-VTE-II studies showed REGN7508Cat had a numerically lower VTE rate compared to apixaban, while REGN9933A2 had a numerically lower VTE rate compared to enoxaparin in TKR patients[33, 36] - In a pooled analysis, REGN7508Cat showed a 13.6% risk difference reduction in VTE incidence compared to pooled enoxaparin[35] - Interim results from the ROXI-CATH study in catheter-associated thrombosis showed a 66% relative risk reduction in VTE with REGN7508Cat versus placebo[40] - A Phase 1 GI bleed study indicated that REGN7508/REGN9933 resulted in 14% less bleeding risk compared to rivaroxaban + aspirin[46] Commercial Opportunity - The current global anticoagulation market is \$20 billion, with standard-of-care DOAC utilization at approximately 50% due to bleeding risk[12] - The U S Factor XI total addressable market in post-TKR VTE is estimated to be ~800K patients, with a ~40% class share anticipated[56, 75] - The U S Factor XI total addressable market in cancer VTE is estimated to be ~300K patients, with a ~30-35% class share anticipated[56, 85]

Exodus Movement, Inc. Forward looking statements This presentation contains "forward-looking statements" as that term is defined by the federal securities laws. All forward-looking statements are based upon our current expectations and various assumptions and apply only as of the date made. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs, and projections will be achi ...